Network Version
MMAD Data Sheet
| Product Name: | MMAD |
 |
|---|---|---|
| CAS No.: | 203849-91-6 | |
| Cat. No.: | HY-15581 | |
| MWt: | 771.06 | |
| Formula: | C41H66N6O6S | |
| Purity : | >98% | |
| Solubility: | DMSO : 24.5 mg/mL (31.77 mM; Need ultrasonic and warming) | |
| Mechanisms: | Target: Cancer | |
| Biological Activity: | ||
| MMAD is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugates (ADCs). IC50 & Target: Tubulin[1] In Vitro: MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity[1]. In Vivo: The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats[1]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com